Precipio Launches New HemeScreen™ Reagent Rental Program
April 06, 2020 10:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 06, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ Reagent Rental (HSRR) program....
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™
September 30, 2019 11:10 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...
Clinical Validations for IV-Cell™ and HemeScreen™ Completed
September 26, 2019 10:53 ET
|
Precipio, Inc.
Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO),...
NTS Ventures and IHMA Announce a Significant and Important Program Focusing on Antifungal Resistance Surveillance: STAR (Susceptibility Trends in Antifungal Resistance)
June 12, 2019 08:00 ET
|
IHMA Inc
SCHAUMBURG, Ill., June 12, 2019 (GLOBE NEWSWIRE) -- NTS Ventures (NTS), a mycology and antifungal clinical research laboratory and International Health Management Associates, Inc./IHMA Europe Sàrl...
Precipio Signs First Major International Services Contract
April 29, 2019 08:35 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has signed a services contract with a health care...
Precipio’s HemeScreen™ Adopted by Methodist Health
April 03, 2019 07:38 ET
|
Precipio, Inc.
NEW HAVEN, Conn., April 03, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected...
Precipio Expands ICE COLD-PCR™ Menu for Breast, Colon and Endometrial Cancers
October 23, 2018 09:15 ET
|
Precipio, Inc.
Ultra-sensitive assays for PIK3CA exons 9 & 20 detect mutations that impact critical therapeutic decisions NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Precipio, Inc. (NASDAQ: PRPO),...
Precipio Launches HemeScreen™, a Disruptive, Proprietary Molecular Test for Hematologic Cancers
October 03, 2018 07:47 ET
|
Precipio, Inc.
Impacts a $100M annual US laboratory market by reducing testing costs through a simple, screening assay NEW HAVEN, Conn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company...
HiberGene Completes Group B Streptococcus Study with National Maternity Hospital
January 12, 2017 04:15 ET
|
HiberGene Diagnostics Ltd
DUBLIN, Ireland, Jan. 12, 2017 (GLOBE NEWSWIRE) -- A joint study conducted by Dublin-based molecular diagnostics manufacturer HiberGene and the National Maternity Hospital (NMH), Dublin has found...
HiberGene Launches HG C. Difficile Test
December 15, 2016 04:55 ET
|
HiberGene Diagnostics Ltd
DUBLIN, Ireland, Dec. 15, 2016 (GLOBE NEWSWIRE) -- HiberGene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has...